Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study

Xiao, Xiaoyan; Cui, Xiaopei; Zhang, Jianbo; Han, Zhenxia; Yu, Xiao; Chen, Nan; Li, Baoying; Cheng, Minna; Gao, Haiqing; Tang, Kuanxiao

doi:10.3892/etm.2016.3729

Cited by 4 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 25.2 ± 2.225.9 ± 3.47 ± 0.57.3 ± 0.459.6 ± 6.755.8 ± 6.688.2 ± 18102.6 ± 27Xiao et al . 14 28.34 ± 3.8127.92 ± 3.877.32 ± 1.017.27 ± 1.1568.7 ± 6.369.1 ± 6.5145.08 ± 21.24148.86 ± 21.78Kim NH et al . 9 25.8 ± 2.727.4 ± 4.37.2 ± 0.27.4 ± 0.459.9 ± 10.252.1 ± 11.193.8 ± 3898.7 ± 31.8Park KS et al .…”

Section: Resultsmentioning

confidence: 99%

“…The total number of included patients was 304, and all were Asian T2DM patients. Five of the seven studies 9,10,13,15,16 were conducted in the Republic of Korea, one 14 in China, and one 17 in Japan. Sample sizes ranged from 25 to 62 individuals.…”

Section: Resultsmentioning

confidence: 99%

“…Sample sizes ranged from 25 to 62 individuals. Two studies 10,14 were performed in patients who underwent initial combination therapy combining DPP-IV inhibitors or other OADs with metformin. Four studies 9,13,15,16 added DPP-IV inhibitors or other OADs to metformin as stepwise add-on therapy for treating T2DM patients.…”

Section: Resultsmentioning

confidence: 99%

“…The timing of mean amplitude of glycemic excursion (MAGE) measurements by continuous glucose monitoring system (CGMS) was commonly at 2–3 days at the baseline and at the end of treatment in the included studies. Six of the included studies 9,10,13,14,16,17 were parallel designs, and one 15 was a crossover study.…”

Section: Resultsmentioning

confidence: 99%

“…13 2013Republic of Korea16/17SitagliptinGlimepirideAdd-onParallel4For 3 successive days at baseline and at the end of follow-upXiao et al . 14 2016China23/18SitagliptinGlimepirideCombinationParallel24For 72 hours, at baseline, 4, 8, 12, and 24- weeksKim NH et al . 9 2017Republic of Korea14/11VildagliptinPioglitazoneAdd-onParallel16For 3 consecutive days at baseline and at the end of follow-upPark KS et al .…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis

Lee

Kim

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Glycemic variability (GV) has been an emerging target for preventing complications related to type 2 diabetes. For reducing GV, DPP-IV inhibitors have shown effectiveness compared to other oral anti-hyperglycemic drugs (OADs), but systematic evaluation has yet to be existed. A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to evaluate the effect of DPP-IV inhibitors compared with other OADs, on GV as measured by mean amplitude of glycemic excursions (MAGE). Searches were conducted using Pubmed, EMBASE, and the Cochrane Library, from which eligible studies were retrieved; seven RCTs were included in the analysis. DPP-IV inhibitors were found to significantly reduce MAGE compared to other OADs (mean difference = −14.61; 95% CI = −19.00 to −10.21; p < 0.0001) without significant heterogeneity among sulfonylureas (mean difference = −14.93; 95% CI = −21.60 to −8.26; p < 0.0001). Initial combination therapy with DPP-IV inhibitors more effectively reduced MAGE than stepwise add-on therapies (p = 0.006), although no differences in MAGE were found based on HbA1c values. These findings indicate that DPP-IV inhibitors are promising alternatives for reducing GV in type 2 diabetes patients. However, further studies utilizing larger numbers of patients and longer-term follow-ups are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis

Lee

Kim

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis

Purja

Shin

et al. 2022

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

While hemoglobin A1c (HbA1c) is commonly used to monitor therapy response in type 2 diabetes (T2D), GV is emerging as an essential additional metric for optimizing glycemic control. Our goal was to learn more about the impact of hypoglycemic agents on HbA1c levels and GV in patients with T2D. A systematic review and network meta-analysis (NMA) of randomized controlled trials were performed to assess the effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter (SGLT)-2 inhibitors, dipeptidyl peptidase (DPP)-4 inhibitors, sulfonylurea and thiazolidinediones on Mean Amplitude of Glycemic Excursions (MAGE) and HbA1c. Searches were performed using PubMed and EMBASE. A random-effect model was used in the NMA, and the surface under the cumulative ranking was used to rank comparisons. All studies were checked for quality according to their design and also for heterogeneity before inclusion in this NMA. The highest reduction in MAGE was achieved by GLP-1 RAs (SUCRA 0.83), followed by DPP-4 inhibitors (SUCRA: 0.72), and thiazolidinediones (SUCRA: 0.69). In terms of HbA1c reduction, GLP-1 RAs were the most effective (SUCRA 0.81), followed by DPP-4 inhibitors (SUCRA 0.72) and sulfonylurea (SUCRA 0.65). Our findings indicated that GLP-1 RAs have relatively high efficacy in terms of HbA1c and MAGE reduction when compared with other hypoglycemic agents and can thus have clinical application. Future studies with a larger sample size and appropriate subgroup analyses are warranted to completely understand the glycemic effects of these agents in various patients with T2D. The protocol for this systematic review was registered with the International Prospective Register of Systematic Reviews (CRD42021256363).

show abstract

Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

Chai¹,

Zhang²,

Zhang³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveThe influence of dipeptidyl peptidase-4 (DPP4) inhibitors on glycemic variability compared to other oral antidiabetic drugs (OADs), measured based on the mean amplitude of glycemic excursions (MAGE), has not been comprehensively analyzed. The aim of the study was to perform a meta-analysis to compare the effects of DPP4 inhibitors on MAGE with other OADs in type 2 diabetes mellitus (T2DM) patients without concurrent insulin treatments.MethodsThe Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library) databases were searched for relevant randomized controlled trials (RCTs). Study characteristics and outcome data were independently extracted by two authors. A random-effect model was used to combine the results.ResultsFourteen studies with 855 patients were included. Compared to other OADs, DPP4 inhibitors significantly reduced MAGE (mean difference [MD]: -0.69 mmol/L, 95% confidence interval [CI]: -0.95 to -0.43, P<0.001) with mild heterogeneity (I2 = 28%). Predefined subgroup analyses suggested that DPP4 inhibitors were more effective in reducing MAGE compared to insulin secretagogues (MD: -0.92 mmol/L, P<0.001) and non-secretagogues (MD: -0.43 mmol/L, P=0.02), as well as compared to sulfonylureas (MD: -0.91 mmol/L, P<0.001) and sodium glucose cotransporter 2 inhibitors (MD: -0.67 mmol/L, P=0.03).ConclusionsDPP4 inhibitors may significantly reduce glycemic variability compared to other oral anti-diabetic drugs, as evidenced by MAGE in T2DM patients with no concurrent insulin treatment.Systematic review registrationINPLASY, registration number: INPLASY2021120113.

show abstract

Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study

Cited by 4 publications

References 33 publications

Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis

Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis

Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis

Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About